Horizon Discovery and Mirna Therapeutics to Test Activities of Tumor Suppressor MicroRNAs
Horizon’s X-MANTM human cell lines will be used to define the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.
One of the challenges that cancer researchers face in developing cancer therapeutics is that of predicting which patient sub-groups will respond to future drug treatments. Horizon’s novel, genetically-defined X-MANTM human cell lines (or “patients-in-a-test-tube”) will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.
This project is funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Commercialization grant.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.